Pfizer Bets On Biosimilars
Pfizer CEO Ian Read is dipping into the pharma giant’s big reserve of cash to gobble up Hospira ($HSP), one of the pioneers in the move to develop biosimilars of blockbuster biologics. The Big Pharma is paying $90 a share… Continue Reading